Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events	From screening until the final follow up visit (day 50)	To assess safety and tolerability of GLPG1972 in OA patients
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs	From screening until the final follow up visit (day 50)	To assess safety and tolerability of GLPG1972 in OA patients
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations	Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)	To assess safety and tolerability of GLPG1972 in OA patients
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination	Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50	To assess safety and tolerability of GLPG1972 in OA patients
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG	Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)	To assess safety and tolerability of GLPG1972 in OA patients
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment	Day -1 to days 1 and Day 10 to day 11	To assess safety and tolerability of GLPG1972 in OA patients
Primary	The maximum observed plasma concentration of GLPG1972 (Cmax)	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43	To assess PK of GLPG1972 in OA patients
Primary	The time (tmax) to reach Cmax of GLPG1972	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43	To assess PK of GLPG1972 in OA patients
Primary	The plasma concentration of GLPG1972 24 after the last dose	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43	To assess PK of GLPG1972 in OA patients
Primary	The area under the plasma concentration time curve from time 0 until the last quantifieble dose	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43	To assess PK of GLPG1972 in OA patients
Secondary	Percentage reduction of neo-epitope ARGS vs baseline	Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)	To assess PD of GLPE1972 in OA patients

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03311009/registered

API reference For AI assistants